32675993|t|Valproic acid rechallenge after valproate-induced hyperammonemic encephalopathy.
32675993|a|A 24-year-old man with a past medical history of behavioral disturbances and spastic tetraplegia secondary to traumatic brain injury presented to the psychiatry consult service with acute exacerbation of agitation and aggression. The patient's behavioral disturbances were previously reduced with 1500 mg daily of valproic acid (VPA). Prior to admission, VPA was discontinued due to elevated serum ammonia levels of 96 mumol/L and clinical findings consistent with valproate-induced hyperammonemic encephalopathy (VIHE), such as lethargy, confusion, frank delirium, and ataxia. Current guidelines for treating VIHE suggest either a complete discontinuation of the drug or a drug rechallenge with the addition of levocarnitine or carglumic acid supplementation. In this case, VPA was rechallenged without supplementation to decrease the risk of noncompliance. The patient received a lower dose of VPA with subsequent up-titration. His ammonia level decreased to an acceptable level. This case report discusses the challenges of managing VIHE in patients requiring VPA and discusses opportunities for further research in preventing VIHE.
32675993	0	13	Valproic acid	Chemical	MESH:D014635
32675993	32	41	valproate	Chemical	MESH:D014635
32675993	50	79	hyperammonemic encephalopathy	Disease	MESH:D001927
32675993	95	98	man	Species	
32675993	130	153	behavioral disturbances	Disease	MESH:D001523
32675993	158	177	spastic tetraplegia	Disease	MESH:D011782
32675993	191	213	traumatic brain injury	Disease	MESH:D000070642
32675993	285	294	agitation	Disease	MESH:D011595
32675993	299	309	aggression	Disease	MESH:D010554
32675993	315	322	patient	Species	9606
32675993	325	348	behavioral disturbances	Disease	MESH:D001523
32675993	395	408	valproic acid	Chemical	MESH:D014635
32675993	410	413	VPA	Chemical	MESH:D014635
32675993	436	439	VPA	Chemical	MESH:D014635
32675993	479	486	ammonia	Chemical	MESH:D000641
32675993	546	555	valproate	Chemical	MESH:D014635
32675993	564	593	hyperammonemic encephalopathy	Disease	MESH:D001927
32675993	595	599	VIHE	Disease	MESH:C536525
32675993	610	618	lethargy	Disease	MESH:D053609
32675993	637	645	delirium	Disease	MESH:D003693
32675993	651	657	ataxia	Disease	MESH:D001259
32675993	691	695	VIHE	Disease	MESH:C536525
32675993	793	806	levocarnitine	Chemical	MESH:D002331
32675993	810	824	carglumic acid	Chemical	MESH:C528449
32675993	856	859	VPA	Chemical	MESH:D014635
32675993	944	951	patient	Species	9606
32675993	977	980	VPA	Chemical	MESH:D014635
32675993	1015	1022	ammonia	Chemical	MESH:D000641
32675993	1117	1121	VIHE	Disease	MESH:C536525
32675993	1125	1133	patients	Species	9606
32675993	1144	1147	VPA	Chemical	MESH:D014635
32675993	1211	1215	VIHE	Disease	MESH:C536525
32675993	Negative_Correlation	MESH:D014635	MESH:D001523
32675993	Negative_Correlation	MESH:D014635	MESH:D003693
32675993	Positive_Correlation	MESH:D014635	MESH:D053609
32675993	Positive_Correlation	MESH:D014635	MESH:D001927
32675993	Negative_Correlation	MESH:D014635	MESH:D001259
32675993	Negative_Correlation	MESH:D014635	MESH:C536525
32675993	Negative_Correlation	MESH:D002331	MESH:C536525
32675993	Negative_Correlation	MESH:D000641	MESH:D014635
32675993	Negative_Correlation	MESH:C528449	MESH:C536525

